Zoetis (ZTS) Cash from Financing Activities (2012 - 2026)

Zoetis' (ZTS) quarterly Cash from Financing Activities came in at -$840.0 million in Q1 2026, down 24.08% year-on-year from -$1.1 billion in Q1 2025, and down 69.7% on a QoQ basis from -$495.0 million in Q4 2025.

Zoetis (ZTS) Cash from Financing Activities (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has 15 years of Cash from Financing Activities data on file, last reported at -$840.0 million in Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 24.08% year-over-year to -$840.0 million in Q1 2026; TTM through Mar 2026 was -$2.0 billion, a 27.73% increase from a year earlier, with the FY2025 full-year figure at -$1.9 billion, up 29.7% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at -$840.0 million, down from -$495.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ZTS reached as high as $780.0 million in Q4 2022 and fell as low as -$1.8 billion in Q1 2023.
  • Historically, Cash from Financing Activities has averaged -$551.9 million across 5 years, with a median of -$545.0 million in 2022.
  • Across the five-year window, Cash from Financing Activities soared 348.41% in 2022 and tumbled 230.64% in 2023, its largest moves.
  • Year by year, Cash from Financing Activities stood at $780.0 million in 2022, then sank by 150.9% to -$397.0 million in 2023, then slumped by 87.66% to -$745.0 million in 2024, then surged by 33.56% to -$495.0 million in 2025, then tumbled by 69.7% to -$840.0 million in 2026.
  • Per Business Quant data, the three most recent Cash from Financing Activities figures were -$840.0 million in Q1 2026, -$495.0 million in Q4 2025, and -$134.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn -4.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -840.00 Mn
Mar 31, 2026 -840.00 Mn
Dec 31, 2025 -495.00 Mn
Dec 31, 2025 -495.00 Mn
Sep 30, 2025 -134.00 Mn
Sep 30, 2025 -134.00 Mn
Jun 30, 2025 -564.00 Mn
Jun 30, 2025 -564.00 Mn
Mar 31, 2025 -677.00 Mn
Mar 31, 2025 -677.00 Mn
Dec 31, 2024 -745.00 Mn
Dec 31, 2024 -745.00 Mn
Sep 30, 2024 -628.00 Mn
Sep 30, 2024 -628.00 Mn
Jun 30, 2024 -763.00 Mn
Jun 30, 2024 -763.00 Mn
Mar 31, 2024 -524.00 Mn
Mar 31, 2024 -524.00 Mn
Dec 31, 2023 -397.00 Mn
Dec 31, 2023 -397.00 Mn